Johnson & Johnson
JNJ
$265.58
-0.29%
Johnson & Johnson is the world's largest and most diversified healthcare company, operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Following the 2023 divestiture of its consumer health business (Kenvue), the company now focuses on high-growth areas in immunology, oncology, neurology, and surgical robotics, positioning itself as a pure-play healthcare innovator. The current investor narrative centers on the company's successful pipeline execution, highlighted by recent FDA clearance for its surgical robot and a proposed talc settlement that removes a major legal overhang, while management targets $100 billion in revenue. With a 64th consecutive annual dividend increase and strong earnings momentum, JNJ is being viewed as a compelling blend of defensive stability and growth potential, though its elevated valuation has sparked debate about whether the stock is overextended after a significant run-up.…
JNJ
Johnson & Johnson
$265.58
Related headlines
JNJ 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $277.91 and implied upside of +4.6% versus the current price.
Average Target
$277.91
0 analysts
Implied Upside
+4.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$190 - $320
Analyst target range
The analyst price targets range from a low of $190.00 to a high of $320.00, representing a wide 68.4% spread from the low to the high, indicating significant uncertainty about the company's future performance. The low target of $190 implies a 31% downside from current levels, likely reflecting concerns about competitive pressures, regulatory risks, or a potential recession impacting device sales. The high target of $320 implies a 16.3% upside, suggesting that some analysts see substantial room for growth driven by pipeline successes, surgical robot adoption, and potential margin expansion. Recent ratings actions have been predominantly positive, with upgrades from Leerink Partners (from Market Perform to Outperform) and reaffirmations of Buy/Overweight ratings from RBC Capital, TD Cowen, Morgan Stanley, and Citigroup, indicating growing institutional confidence in the stock's prospects.
JNJ Technical Analysis
Johnson & Johnson is in a powerful sustained uptrend, with the stock up 53.97% over the past year, dramatically outperforming the S&P 500's 18.65% gain. The current price of $275.23 sits just 2.1% below its 52-week high of $281.07 and 58.8% above its 52-week low of $173.33, indicating the stock is trading near the top of its range. This positioning near highs reflects strong momentum and investor confidence, though it also raises the risk of short-term overextension, especially given the stock's low beta of 0.231, which suggests the move is driven by company-specific catalysts rather than broad market forces.
Beta
0.23
0.23x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$173-$281
Price range past year
Annual Return
+48.8%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | +1.8% | -1.1% |
| 3m | +10.3% | +3.0% |
| 6m | +10.0% | +15.4% |
| 1y | +48.8% | +16.2% |
| ytd | +28.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Johnson & Johnson's revenue growth has accelerated, with Q1 2026 revenue of $24.06 billion representing 9.91% year-over-year growth, up from the 2.3% growth seen in Q4 2025. The Innovative Medicine segment led with $15.43 billion in revenue, while MedTech contributed $8.64 billion, reflecting the company's strategic focus on high-growth pharmaceutical and device markets. This acceleration is driven by strong demand for oncology and immunology treatments, as well as the launch of new surgical robotics products, positioning the company for sustained mid-single-digit to high-single-digit growth.
Quarterly Revenue
$24.1B
2026-03
Revenue YoY Growth
+9.9%
YoY Comparison
Gross Margin
71.5%
Latest Quarter
Free Cash Flow
$17.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given Johnson & Johnson's positive net income of $5.24 billion in Q1 2026, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 18.82x, while the forward PE is 22.36x, indicating that the market expects earnings growth to moderate or that current earnings are temporarily elevated due to one-time gains. The gap between trailing and forward PE suggests the market is pricing in a slight deceleration in earnings, which is typical for a mature healthcare company, but the PEG ratio of 0.21 implies that the stock is undervalued relative to its expected growth rate, signaling potential upside if growth persists.
PE
18.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple